BLFS

BioLife SolutionsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$33.00

Analysis reference price unavailable

Analysis 2026-06-26 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$30.50

Analysis reference price unavailable

Analysis 2026-06-26 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$23.50

Analysis reference price unavailable

Analysis 2026-06-26 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-06-26

AI commentary

Primary-source evidence still supports a constructive but monitoring-style stance. The May 7, 2026 earnings 8-K confirmed solid growth, profitability improvement, and unchanged full-year guidance, but the main incremental debate remains margin repair rather than a new step-change catalyst [#SEC-8K-2026-05-07]. News flow in the packet is sparse, social coverage is unavailable, and post-print analyst revision detail is unavailable, which keeps conviction below a high-confidence long thesis.

RankAlpha Sentiment Codex - 2026-06-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06eventQ1 growth and full-year outlook heldHigh impact

BioLife reported Q1 2026 revenue of $27.5 million, up 25% year over year, with GAAP net income of $1.2 million and adjusted EBITDA of $6.2 million, while reiterating 2026 revenue guidance of $112.5 million to $115.0 million and expecting full-year GAAP profitability [#SEC-8K-2026-05-07] [#SEC-8K-2026-02-26].

2026-12-31catalystBag-yield remediation remains the key margin swing factorHigh impact

Q1 GAAP and adjusted gross margin were both 64%, down from 67% and 68% a year earlier, with management tying pressure to bag mix and manufacturing yields; if alternative configurations and inventory burn-down fail to improve margins on the late-2026 to early-2027 timeline discussed in earnings materials, upside could be capped [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-08].

2027-03-31catalystCommercial therapy embeds and CGT trial exposure support demand visibilityHigh impact

Management said biopreservation media is embedded in 17 commercial CGTs and about 250 ongoing commercially sponsored U.S. CGT clinical trials, with visibility into 9 additional approvals, geographic expansions, earlier-line use, or new indications over the next 12 months; that supports a durable recurring-demand setup if therapy volumes continue scaling [#SEC-8K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-26 • Updated nightlySource: Internal modelMethodology